Pharmascience Canada is proud to launch generic drug pms-EVEROLIMUS 2.5 mg, 5 mg and 10 mg

Pharmascience Canada, one of Pharmascience Inc division, is proud to launch generic drug pms-EVEROLIMUS 2.5 mg, 5 mg and 10 mg. This product is the generic bioequivalent to AFINITOR®.

 

Here are the indications for this product:

– Treatment of postmenopausal women with hormone receptor-positive, HER2- negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole;

– Treatment of well- or moderately differentiated neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease that has progressed within the last 12 months;

– Treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease;

– Treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell morphology, after failure of initial treatment with either of the vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-receptor TKIs) sunitinib or sorafenib;

– Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgical intervention is not required.

– Treatment of adult patients (≥ 18 years of age) with renal angiomyolipoma associated with tuberous sclerosis complex (TSC), who do not require immediate surgery;

“Pharmascience is proud to launch pms-EVEROLIMUS, the lower cost alternative to AFINITOR®. We continue to invest in generic oncology products in support of the fight against cancer.” – Sandra Sanhye, Product Manager at Pharmascience Canada.

There will not be a Patient Support program for pms-EVEROLIMUS at this time.

 

ABOUT PHARMASCIENCE INC.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2020, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People and named as one of Montreal’s best employers, as part of the Canada’s Top 100 Employers project. Also, in 2020, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers.

AFINITOR® is a registered trademark of Novartis AG.

For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.